Compile Data Set for Download or QSAR
Report error Found 504 of affinity data for UniProtKB/TrEMBL: Q9NXS2
LigandPNGBDBM50652793(CHEMBL5653589)
Affinity DataKd:  5.80nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
LigandPNGBDBM687826(US20240246981, Example 54)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687832(US20240246981, Example 60)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687841(US20240246981, Example 69)
Affinity DataIC50: 0nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM652300(US20240059675, Example 4)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652305(US20240059675, Example 8)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652310(US20240059675, Example 13)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652312(US20240059675, Example 15)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652313(US20240059675, Example 16)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652318(US20240059675, Example 21)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652324(US20240059675, Example 26)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM652363(US20240059675, Example 32)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

LigandPNGBDBM687778(US20240246981, Example 6)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687791(US20240246981, Example 19)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687794(US20240246981, Example 22)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687802(US20240246981, Example 30)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM661126(US20240101544, Example 11 | 2-[4-(4-methyl-4H-1,2,...)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687805(US20240246981, Example 33)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687806(US20240246981, Example 34)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687808(US20240246981, Example 36)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687812(US20240246981, Example 40)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687822(US20240246981, Example 50)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687825(US20240246981, Example 53)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687827(US20240246981, Example 55)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687828(US20240246981, Example 56)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687830(US20240246981, Example 58)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687834(US20240246981, Example 62)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687835(US20240246981, Example 63)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687844(US20240246981, Example 72)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687846(US20240246981, Example 74)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687847(US20240246981, Example 75)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687848(US20240246981, Example 76)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687853(US20240246981, Example 81)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687855(US20240246981, Example 83)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM687858(US20240246981, Example 86)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

LigandPNGBDBM762870(US20250250252, Example 1)
Ligand Info
In Depth
Date in BDB:
TBA
Entry Details
LigandPNGBDBM637725(US11834440, Compound 7B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637754(US11834440, Compound 8B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637814(US11834440, Compound 14B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637816(US11834440, Compound 15B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637817(US11834440, Compound 16CR)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637820(US11834440, Compound 17B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637822(US11834440, Compound 18B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637823(US11834440, Compound 22)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637825(US11834440, Compound 22B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637827(US11834440, Compound 25CR)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637834(US11834440, Compound 32B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637835(US11834440, Compound 34CR)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637838(US11834440, Compound 35B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

LigandPNGBDBM637839(US11834440, Compound 42B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

Displayed 1 to 50 (of 504 total ) | Next | Last >>
Jump to: